SINGAPORE (Nov 26): Biolidics, a cancer diagnostic solutions developer and an associate company of Clearbridge Health, on Friday lodged a preliminary prospectus for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.

Biolidics, incorporated as Clearbridge Biomedics in 2009, specialises in developing cell enrichment systems that can be combined with other analytical tests for cancer diagnosis, prognosis and treatment selection and monitoring.

Biolidics’ flagship product is the ClearCell FX1 System, a fully automated in vitro diagnostic medical device that separates and enriches cancer cells from blood to perform liquid biopsies.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook